Evidence map›Paper›PMID 40349182›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2025

Mesoporous Gold Nanospheres Confined Platinum Nanoclusters as Robust ROS and Oxygen Nanogenerators for NIR-II Hyperthermia Cancer Therapy.

Fei Cun, Jie Chen, Hanxue Li, Yufang Kou, Meiyan Wang, Xiaomin Li, Hui Chen, Jilie Kong

Abstract read
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Fei CunDepartment of Chemistry, Fudan University, Shanghai, 200438, China.
Jie ChenDepartment of Chemistry, Fudan University, Shanghai, 200438, China.
Hanxue LiDepartment of Chemistry, Fudan University, Shanghai, 200438, China.
Yufang KouDepartment of Chemistry, Fudan University, Shanghai, 200438, China.
Meiyan Wang411 Hospital, School of Medicine, Shanghai University, Shanghai, 200444, China.
Xiaomin LiDepartment of Chemistry, Fudan University, Shanghai, 200438, China.ORCID https://orcid.org/0000-0001-6056-6928
Hui ChenDepartment of Chemistry, Fudan University, Shanghai, 200438, China.
Jilie KongDepartment of Chemistry, Fudan University, Shanghai, 200438, China.

Funding

National Natural Science Foundation of China 22127806National Natural Science Foundation of China 22174022National Natural Science Foundation of China 22274028National Natural Science Foundation of China 32171414Nature Science Foundation of Chongqing, China CSTB2022NSCQ-MSX0461Shanghai Natural Science Foundation 20ZR1403000Shanghai Natural Science Foundation 23ZR1419500Shanghai Science and Technology Innovation Action Plan 20392001900
6 · The paper itself

Abstract

While massive studies are focused on platinum (Pt)-based nanozyme for antitumor therapies, their therapeutic efficiency is deficient due to the weak catalytic activity in the highly complex tumor microenvironment. Herein, mesoporous gold nanospheres confined platinum nanoclusters (MGNSs@Pt) as robust hydroxyl radical and oxygen nanogenerators are achieved for multimodal therapies. Benefiting from the confinement effect of the mesopores in the MGNSs, the Pt nanoclusters (Pt NCs) demonstrate enhanced stability and catalytic activity, with a catalytic constant (K

Indexed as

GoldHyperthermia, InducedMetal NanoparticlesNanospheresNeoplasmsOxygenPlatinumReactive Oxygen SpeciesAnimalsCell Line, TumorHumansMiceGoldOxygenPlatinumReactive Oxygen Speciescatalytic therapyconfinement effectmesoporous goldphotothermal therapyplatinum nanozymes

Identifiers

PMID40349182
PMCPMC12302635

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.